TY - JOUR
AU - Custovic, A.
AB - What is already known about this topic?Aeroallergen exposure control measures, such as mite‐proof bedding, acaricides, air‐filtration devices, are of limited benefit in atopic eczema. Overnight temperature‐controlled laminar airflow treatment reduces personal allergen exposure and can improve severe atopic asthma.What does this article add to our knowledge?Reduction of allergen and particle exposure in the breathing zone using overnight temperature‐controlled laminar airflow treatment may substantially improve severe atopic eczema.How does this study impact current management guidelines?Overnight TLA device treatment could be considered as an effective add‐on to standard pharmacological management of difficult‐to‐control atopic eczema. A randomized controlled trial is urgently required.INTRODUCTIONThe prevalence of atopic eczema (AE) in children and adolescents has been reported to be as high as 24%, with up to a quarter of patients having moderately severe disease, and 2%‐7% being severely affected. Persistence of early‐life AE beyond the age of 8 years occurs in 20% of patients, and in 5% for ≥20 years; however in children with severe disease, persistence rates are above 50%. Comorbidities, such as allergic rhinoconjunctivitis and asthma, are common, particularly amongst the more severely affected children, and have additional adverse impact on already impaired quality of life of patients and their families. Healthcare costs associated with 
TI - Temperature‐controlled laminar airflow (TLA) device in the treatment of children with severe atopic eczema: Open‐label, proof‐of‐concept study
JF - Clinical & Experimental Allergy
DO - 10.1111/cea.13105
DA - 2018-01-01
UR - https://www.deepdyve.com/lp/wiley/temperature-controlled-laminar-airflow-tla-device-in-the-treatment-of-lVAX1SlYit
SP - 594
EP - 603
VL - 48
IS - 5
DP - DeepDyve
ER -